IP Library Granted Patent US 8,575,306
Granted Patent B2
US 8,575,306 · App. 13/482,149 · Granted Nov 5, 2013

Target and method for inhibition of bacterial RNA polymerase

Inventor: Richard H. Ebright (North Brunswick, NJ)
Assignee: Rutgers, The State University of New Jersey
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,575,306
App. No.
13/482,149
Granted
Nov 5, 2013
Kind
B2
Abstract

Target and method for inhibition of bacterial RNA polymerase disclosed are targets and methods for specific binding and inhibition of RNAP from bacterial species.

Claims (5)

1. An isolated analog of bacteriocidal-peptide microcin J25 (MccJ25) that (1) has an amino acid sequence that differs from that of MccJ25 in terms of at least one amino acid substitution, insertion, or deletion; and (2) that binds a bacterial RNAP and inhibits an activity of bacterial RNAP with a potency at least equal to that of MccJ25 wherein the analog is selected from the group consisting of [Lys 5 ]MccJ25, [Lys 13 ]MccJ25, [Lys 15 ]MccJ25, and [Lys 17 ]MccJ25.

2. The isolated analog according to claim 1 that also contains a detectable group.

3. The isolated analog according to claim 2 wherein the detectable group is selected from the group consisting of a chromophore, fluorophore and Cy3.

4. An isolated analog of bacteriocidal-peptide microcin J 25 (MccJ25) that (1) has an amino acid sequence that differs from that of MccJ25 in terms of at least one amino acid substitution, insertion, or deletion; and (2) that binds a bacterial RNAP and inhibits an activity of bacterial RNAP with a potency at least equal to that of MccJ 25 wherein the analog is selected from the group consisting of [X-Lys 5 ]MccJ25, [X-Lys 13 ]MccJ25, [X-Lys 15 ]MccJ25, and [X-Lys 17 ]MccJ25, wherein X is a detectable group.

5. The isolated analog according to claim 4 wherein the detectable group is selected from the group consisting of a chromophore, fluorophore and Cy3.

Assignments (1)
CONFIRMATORY LICENSE Recorded Feb 4, 2022
From: RUTGERS, THE STATE UNIV. OF N.J.
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR, DEITR
Reel/Frame 058884/0312 →
Continuity (6)
Division 12257801 · Oct 24, 2008
Continuation 10526323
Provisional Application 60474608 · Jun 2, 2003
Provisional Application 60474607 · Jun 2, 2003
Provisional Application 60407684 · Sep 4, 2002
Related Publication 20130030152A1 · Jan 31, 2013